Clinical Trial Update: Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) [Phase 1]

View source ↗

Summary

Phase I trial evaluating three grams daily valacyclovir in patients with chronic hepatitis C and HSV-2 infection has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Herpes Simplex Virus Type Infection

Drugs mentioned

• Valacyclovir (Valacyclovir)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Chronic Hepatitis C Infection | Phase 1 | Status: COMPLETED | Results posted: 2016-11-22